MBIO Mustang Bio

Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)

Mustang Bio Announces First Patient Dosed in Multicenter Phase 1/2 Clinical Trial of MB-102 (CD123-targeted CAR T Cell Therapy)
EN
01/10/2020

Underlying

MBIOMustang Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Mustang Bio

 PRESS RELEASE
Free
MBIO MUSTANG BIO

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement

Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1). On February 26, 2025, Mustang received formal notice from Nasdaq confirming that the Company has satisfied the minimum stockholders’ equity requirem...

March 5, 2025 1 EN
 PRESS RELEASE
Free
MBIO MUSTANG BIO

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility

Mustang Bio Announces Sale of Fixed Assets and Exit of Facility WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the exit of the lease for its manufacturing facility in Worcester, Massachusetts and concurrent divestment of certain fixed assets including furniture and equipment to AbbVie Bioresearch Center Inc., a Delaware corporation (“AbbVie”), ...

February 27, 2025 1 EN
 PRESS RELEASE
Free
MBIO MUSTANG BIO

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requireme...

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement WORCESTER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO) today announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing. In addition, as a result of the closing of the public offering announced by the Company on February 10, 2025, the Company believes that it has a minimum of $2.5 milli...

February 11, 2025 1 EN
 PRESS RELEASE
Free
MBIO MUSTANG BIO

Mustang Bio Announces Closing of $8 Million Public Offering

Mustang Bio Announces Closing of $8 Million Public Offering WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering, for the issuance and sale of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 sha...

February 10, 2025 1 EN
 PRESS RELEASE
Free
MBIO MUSTANG BIO

Mustang Bio Announces Pricing of $8 Million Public Offering

Mustang Bio Announces Pricing of $8 Million Public Offering WORCESTER, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced the pricing of a public offering of an aggregate of 2,657,807 shares of its common stock (or common stock equivalents in lieu thereof), Series C-1 warrants to purchase up to 2,657,807 shares of common stock and Series C-2 warrants to pur...

February 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch